Loading...

PODCAST

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts,

science life sciences

All Episodes

00:10:16

Apr 02, 2026 | Trump's 100% Drug Tariff Splits...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/03

Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval as analysts project blockbuster launch. Lilly-Centessa ($6.3B) andBiogen-Apellis ($5.6B) deals cap a $25.5B acquisition spree.visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Trump pharma tariff, pharmaceutical tariffs, Eli Lilly, Foundayo,

en-us

00:10:19

Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/02

Lilly's Foundayo becomes the first oral GLP-1 approved forobesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoints in thyroid eye disease. Plus: Merck-Infinimmune $838M antibody deal, Blackstone's record $6.3B life sciences fund, and the WhiteHouse readies 100% tariffs on imported brand-name drugs.www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo,

en-us

00:09:30

Mar 31, 2026 | Lilly's $7.8B Centessa Deal; Biogen...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/01

Eli Lilly acquires Centessa Pharmaceuticals for up to $7.8B,targeting narcolepsy via orexin agonists as part of pharma's $25.5B eight-day buying spree. Biogen bets $5.6B on Apellis complement therapies. FDA warns of 8deaths linked to Amgen's Tavneos liver safety signal.visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Centessa Pharmaceuticals, Biogen, Apellis

en-us

00:09:00

Mar 30, 2026 | Tyvaso's Second Phase 3 Win in IPF;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/31

United Therapeutics' Tyvaso delivers 130.1 mL FVCimprovement in TETON-1, its second Phase 3 win in IPF — filing plans now underway. Plus Viridian's 38% stock crash on REVEAL-1 data, Lilly's $115M upfront AI deal with Insilico Medicine, BridgeBio's 54-month ATTR-CM survivaldata, Biogen's Spinraza HD FDA approval, and CBER untitled letters hitting four major companies.Visit us at www.thepharmacloseout.com Pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals,

en-us

00:13:38

Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/30

Eli Lilly signs $2.75B biobucks deal with Insilico Medicinefor AI-discovered oral therapeutics. AAD 2026 brings 52-week ICOTYDE, zasocitinib Phase 3 psoriasis data, and Sanofi amlitelimab Q12W dosing in atopic dermatitis. Plus HI-PEITHO PE results from ACC and Merck's WINREVAIRCADENCE proof-of-concept.Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, InsilicoMedicine, AI drug

en-us

00:10:35

Mar 27, 2026 | Novo Nordisk's Once-Weekly Insulin...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/28

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen Xolair successor, Otsuka acquires Transcend for $700M upfront, andAstraZeneca's tozorakimab delivers dual Phase 3 wins in COPD. Rocket Pharmaceuticals lands its first gene therapy approval for severe LAD-I.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The

en-us

00:09:27

Mar 26, 2026 | Wave Crashes 58% on Obesity Data Miss;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/27

Wave Life Sciences plunges 58% after WVE-007 higher-doseobesity data fails to separate from lower dose. CVC Capital Partners offers €52/share ($12.6B) to take Recordati private. Plus: Kodiak's Phase 3 GLOW2 diabetic retinopathy win, Corcept's relacorilant approval in ovarian cancer, and FDA "America First" user fee pushback.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:09:19

Mar 25, 2026 | Merck's $6.7B Terns Acquisition for...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/26

Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the first biologic designed to cross the blood-brain barrier — for Hunter syndrome, and Corcept's Lifyorli (relacorilant) for platinum-resistantovarian cancer. Plus Ionis cuts Tryngolza's price 93%.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma

en-us

00:09:23

Mar 24, 2026 | ImmunityBio's Third FDA Warning...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/25

ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines,

en-us

00:09:16

Mar 23, 2026 | Apogee Eczema Data Sends Stock Up 20%;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/23

Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Arikayce ENCORE Phase 3b hits primary endpoint in MAC lung disease. Dizal Zegfrovy pressures J&J's Rybrevant with first-line NSCLC data. Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Apogee Therapeutics, zumilokibart, atopic dermatitis,

en-us

00:11:14

Mar 22, 2026 | Abbott's $21B Exact Sciences Deal...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/23

Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron PDUFA slips to April 10. Plus: GSK's Lynavoy, Pfizer's TALAPRO-3 data, and Genentech's emugrobart setback. Full week-in-review.pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Abbott, Exact Sciences, Cologuard, Oncotype DX, Novo Nordisk, Wegovy HD,

en-us

00:09:42

Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/21

Novartis pays $2B upfront for Synnovation's Phase 1/2 PI3Kα inhibitor SNV4818 to defend its HR+/HER2- breast cancer franchise. Plus: BMS Opdivo wins first immunotherapy combo approval in frontline Hodgkin lymphoma, GSK's Lynavoy becomes first drug for cholestatic pruritus in PBC, and Pfizer's TALAPRO-3 clears Phase 3 in prostate cancer.Visit us at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma

en-us

00:10:32

Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/20

Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M, Pfizer's Talzenna wins in prostatecancer, and Lynavoy gets an early FDA nod.Visit the website at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:09:16

Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/18

FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist

en-us

00:08:55

Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/18

Aldeyra Therapeutics crashes ~68% after the FDA rejectsreproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfizer's atirmociclib shows 40% PFS reduction in post-CDK4/6 breast cancer. Plus: court blocks RFK Jr. vaccine overhaul, MFN pricingreshapes deal structures, and Bicycle retreats from Padcev. Follow the podcast and visit our site at https://thepharmacloseout.com/#pharma,#pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare,

en-us

00:09:39

Mar 16, 2026 | Structure Therapeutics Oral GLP-1 Data...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/17

Structure's aleniglipron delivers 16.3% weight loss in Phase2 — challenging Lilly's orforglipron in the oral GLP-1 race. Plus BioMarin's Voxzogo safety halt, Aldeyra's reproxalap FDA decision, Rhythm's EMANATE miss ahead of Thursday PDUFA, and Bayer's Kerendia CKD expansion win.Visit us at https://thepharmacloseout.com/#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Structure Therapeutics,

en-us

00:12:54

Mar 15, 2026 | Immutep LAG-3 Phase 3 Failure Crashes...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/16

Immutep's LAG-3 drug eftilagimod alfa fails Phase 3 futility analysis in NSCLC—stock drops 88%. Ultragenyx DTX301 gene therapy hits co-primary endpoint in OTC deficiency. Plus: Lilly's $3B orforglipron manufacturing expansion, BridgeBio muscular dystrophy data, and four PDUFA dates ahead.Visit at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Immutep, eftilagimod alfa, LAG-3, NSCLC, Ultragenyx,

en-us

00:10:14

Mar 13, 2026 | GSK Arexvy Expands to At-Risk Adults...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/14

GSK wins FDA clearance to expand Arexvy RSV vaccine to at-risk adults ages 18-49 — the broadest age indication in the RSV market. Plus: Novartis claims the only IL-17A approval for pediatric hidradenitis suppurativa, Pfizer shuts down its small biotech R&D support unit, and why manufacturing is the story to watch as the 2026 patent cliff approachesSubstack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #pharmaceutical, #FDA, #clinical

en-us

00:10:33

Mar 12, 2026 | Ultragenyx Gene Therapy Hits Phase 3...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/13

Ultragenyx's gene therapy clears pivotal trial for raremetabolic disease — a critical win for the gene therapy sector. Lilly invests $3B in China manufacturing for oral GLP-1 and escalates the compounding fight. LAG-3 pioneer fails Phase 3, raising hard questions about the immuno-oncology target. Plus: GSK Arexvy wins expanded RSV approval.Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠Substack:

en-us

00:15:45

The AI Reckoning — Episode 4: Who Wins

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/12

Three competitive strategies. A $135.7 billion Chineseout-licensing signal. Three diverging regulatory frameworks. We pull together everything from the series into a practical framework: which companies arepositioned to win, which strategic models carry the most risk, and what every pharma professional should be doing right now.Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠#pharma, #AI strategy, #competitive advantage, #China pharma,

en-us

174 results

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

Show Me the Science with Luke O"Neill

Newstalk

Planetterrian Daily

Patrick · Nerra Network

Sleep Science

Sleep Science

BioSpace

BioSpace